EUCTR2005-001417-18-HU进行中（未招募）不适用
A phase II Clinical Trial to Evaluate Intratumoral Injection of a Depot Formulation of Paclitaxel (DTS-301) as Neoadjuvant Therapy of Patients with Breast Cancer
DIATOS S.A.0 个研究点目标入组 10 人开始时间: 2006年3月31日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Histologically confirmed invasive primary breast cancer from core needle biopsy
- •Post-menopausal patients with hormone receptor positive tumor meaning estrogen and/or progesterone receptor positive (cut-off: 10% stained cells)
- •Single palpable tumor of 1.5 to 4 cm in diameter
- •Adequate hematological, renal and hepatic functions
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Distant metastases
- •Multicentric and bilateral breast cancer
- •Inflammatory breast disease
- •Previous radiotherapy, surgery, hormonal therapy for breast cancer
- •Previous chemotherapy for malignant disease within the past 3 years
研究者
相似试验
进行中（未招募）
不适用
A Phase II Clinical Trial to Evaluate Intratumoral Injection of a Depot Formulation of Paclitaxel (DTS-301) as Neoadjuvant Therapy of Patients with Breast CancerInvasive primary breast cancerEUCTR2005-001417-18-ATDIATOS S.A.10
终止
1 期
Exploratory Phase Ib/IIa Study of Intratumourally Administered Tigilanol Tiglate to Assess Safety, Tolerability and Tumour Response in Patients with Head and Neck Squamous Cell CarcinomaACTRN12619001407189QBiotics Group Limited19
Unknown
1 期
To study the Safety, Tolerability and Tumour Response when treated with drug Tigilanol Tiglate administered intratumourally in Patients with Head and Neck Squamous Cell Carcinoma.CTRI/2019/11/022032QBiotics Group Limited13
进行中（未招募）
1 期
Study of BO-112 with pembrolizumab for colorectal or gastric /gastro-oesophageal junction cancer with liver metastasisColorectal cancer or gastric/gastro-oesophageal junction cancer with liver metastasisMedDRA version: 21.1Level: PTClassification code 10063916Term: Metastatic gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-004624-38-ESBioncotech Therapeutics, S.69
进行中（未招募）
1 期
Study of BO-112 with pembrolizumab for colorectal or gastric /gastro-oesophageal junction cancer with liver metastasisColorectal cancer or gastric/gastro-oesophageal junction cancer with liver metastasisMedDRA version: 21.1Level: PTClassification code 10063916Term: Metastatic gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-004624-38-DEHighlight Therapeutics, S.69